Judge Orders the FAA to Explain its Ban on Remeron | Aero-News Network
Aero-News Network
RSS icon RSS feed
podcast icon MP3 podcast
Subscribe Aero-News e-mail Newsletter Subscribe

Airborne Unlimited -- Most Recent Daily Episodes

Episode Date

Airborne-Monday

Airborne-Tuesday

Airborne-Wednesday Airborne-Thursday

Airborne-Friday

Airborne On YouTube

Airborne-Unlimited-06.23.25

Airborne-NextGen-06.24.25

AirborneUnlimited-06.25.25

Airborne-AffordableFlyers-06.26.25

AirborneUnlimited-06.27.25

Tue, Jul 01, 2025

Judge Orders the FAA to Explain its Ban on Remeron

Former Airline Pilot Comes Forward After Being Denied a Medical

A D.C. Circuit Judge is ordering the FAA to explain itself after a former airline pilot was denied a medical without receiving any true rationale for the decision. The disqualifying medication, Remeron, seems to carry the same drowsiness-related risks as other antidepressants that the agency takes on a case-by-case basis.

At the center of the case is Michael Solondz: a veteran airline pilot with nearly 20 years of commercial flying experience. After stepping away from the cockpit due to anxiety, Solondz tried Lexapro, an FAA-approved antidepressant, but experienced side effects like dizziness. His doctor switched him to Remeron, which he took at night and tolerated well. When he reapplied for his first-class medical certificate, the FAA denied his request solely based on the use of Remeron, despite Solondz submitting multiple medical evaluations showing no side effects or cognitive impairment.

The FAA’s so-called justification was a single 1998 study suggesting Remeron might impair driving after 16 days of use. Never mind that FAA-approved antidepressants like SSRIs also carry drowsiness risks, yet still earn case-by-case evaluation by regulators. The court, in no uncertain terms, said that the disconnect needs to be addressed.

“The difficulty is that, whereas the Federal Aviation Administration conditionally approved Lexapro, it has categorically disallowed pilots to fly while treated with mirtazapine,” wrote Judge Cornelia Pillard. “The agency must reasonably explain its actions. It has not done so here. The agency has failed to explain why it categorically disallows medical certification to all pilots who take the medication that Solondz was prescribed and finds beneficial.”

The FAA also cited unrelated and inconsistently applied health concerns like sleep apnea and a decades-old atrial fibrillation incident as reasons for denial, raising more questions than answers. The court remanded the case, ordering the FAA to provide a reasoned, evidence-based explanation.

FMI: www.faa.gov

Advertisement

More News

TikToker Arrested After Landing His C182 in Antarctica

19-Year-Old Pilot Was Attempting to Fly Solo to All Seven Continents On his journey to become the first pilot to land solo on all seven continents, 19-year-old Ethan Guo has hit a >[...]

Classic Aero-TV: Versatile AND Practical - The All-Seeing Aeroprakt A-22 LSA

From 2017 (YouTube Edition): A Quality LSA For Well Under $100k… Aeroprakt unveiled its new LSA at the Deland Sport Aviation Showcase in November. Dennis Long, U.S. Importer>[...]

ANN's Daily Aero-Term (06.27.25): Hazardous Weather Information

Hazardous Weather Information Summary of significant meteorological information (SIGMET/WS), convective significant meteorological information (convective SIGMET/WST), urgent pilot>[...]

ANN's Daily Aero-Linx (06.27.25)

Aero Linx: Historic Aircraft Association (HAA) The Historic Aircraft Association (HAA) was founded in 1979 with the aim of furthering the safe flying of historic aircraft in the UK>[...]

Aero-News: Quote of the Day (06.27.25)

"We would like to remember Liam not just for the way he left this world, but for how he lived in it... Liam was fearless, not necessarily because he wasn't afraid but because he re>[...]

blog comments powered by Disqus



Advertisement

Advertisement

Podcasts

Advertisement

© 2007 - 2025 Web Development & Design by Pauli Systems, LC